Watson commences US Phase III study of Esmya
Esmya is a first-in-class, orally active selective progesterone receptor modulator which reversibly blocks progesterone receptors in target tissues. The multi-center randomized double-blind US Phase 3 study included 300
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.